The key moments, with employee sentiment along the way.
2015
🌱
2015
Founded in Mumbai
An online pharmacy delivering medicines and diagnostics across India.
Wikipedia
Apr 2021
🦄
Apr 2021
Joins the unicorn club
Pandemic-era demand for medicine delivery pushes the valuation past $1B.
Inc42
2021
📈
2021
The peak: ~$5.6B$5.6B
Rapid pandemic-era growth and acquisitions push the valuation to roughly $5.6B.
Inc42
2022–23
💬
From the inside · Glassdoor reviews, 2022–23
Glassdoor reviews from the 2022–23 cash crunch described the strain inside: recurring layoff rounds, job insecurity employees tied directly to the company's finances, and frozen hikes alongside stock options worth far less than promised.
2023
2023
A heavily discounted rights issue
Mounting losses and debt force a rights issue at a steep discount, repricing the company far below peak.
Inc42
2023
💔
2023
Slips out of the club
Investor markdowns pile up as the funding reset sinks in.
Inc42
Dec 2024
Dec 2024
Marked to ~$456M
Neuberger Berman's markdown implies a fall of about 92% from peak.
Inc42
💬 entries paraphrase anonymous, unverified reviews posted publicly on Glassdoor ↗; dated facts carry their source.
How it happened
PharmEasy is an Indian online pharmacy and healthtech platform that peaked at roughly $5.6B in 2021 after rapid pandemic-era growth and acquisitions. Mounting losses and debt forced a heavily discounted rights issue and steep investor markdowns; Neuberger Berman cut its stake to imply a valuation near $456M by late 2024, a fall of about 92% from peak.
